Long-acting Inhaledβ2Agonists (LABAs) in Children and the New "Black Box" Warning

Abstract

Pediatric Asthma, Allergy & ImmunologyVol. 19, No. 2 Pharmacotherapy UpdateLong-acting Inhaledβ 2 Agonists (LABAs) in Children and the New "Black Box" WarningH. William KellyH. William KellySearch for more papers by this authorPublished Online:6 Jun 2006https://doi.org/10.1089/pai.2006.19.126AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byThe U.S. Food and Drug Administration (FDA) and the Safety of Salmeterol in Children H.W. Kelly12 September 2008 | Pediatric Asthma, Allergy & Immunology, Vol. 21, No. 2The New National Asthma Education and Prevention Program's Guidelines on the Diagnosis and Management of Asthma and Childhood Asthma Treatment H. William Kelly28 January 2008 | Pediatric Asthma, Allergy & Immunology, Vol. 20, No. 4Budesonide/Formoterol Fumarate (Symbicort®) H. William Kelly28 December 2006 | Pediatric Asthma, Allergy & Immunology, Vol. 19, No. 4LiteratureWatch25 September 2006 | Pediatric Asthma, Allergy & Immunology, Vol. 19, No. 3 Volume 19Issue 2Jun 2006 InformationCopyright 2006, Mary Ann Liebert, Inc.To cite this article:H. William Kelly.Long-acting Inhaledβ 2 Agonists (LABAs) in Children and the New "Black Box" Warning.Pediatric Asthma, Allergy & Immunology.Jun 2006.126-131.http://doi.org/10.1089/pai.2006.19.126Published in Volume: 19 Issue 2: June 6, 2006PDF download